日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis

按体重指数校正的甲氨蝶呤剂量评估托法替尼和阿达木单抗治疗类风湿性关节炎的疗效和安全性：一项事后分析

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-025-00823-0
Takeuchi, Tsutomu; Tanaka, Yoshiya; Yamanaka, Hisashi; Yamaoka, Kunihiro; Sugiyama, Naonobu; Iikuni, Noriko; Toyoizumi, Shigeyuki; Kwok, Kenneth; Tsai, Wen-Chan; Mysler, Eduardo; Moots, Robert J; Smolen, Josef S; Fleischmann, Roy
关节炎
发表日期：2026
文献求助 收藏

Evaluation of the Relationship Between Anemia and Subjective Symptoms in White-Collar Workers

白领工人贫血与主观症状关系的评估

期刊:Cureus Journal of Medical Science
影响因子:1.3
doi:10.7759/cureus.83819
Iikuni, Toshimitsu; Hotaka, Kosuke; Shimazaki, Takashi; Yamauchi, Takashi; Suka, Machi
贫血
代谢
发表日期：2025
文献求助 收藏

Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis

在类风湿性关节炎患者的生物相似性研究中使用多生物标志物疾病活动评分

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2022-002423
Kay, Jonathan; Bock, Amy E; Rehman, Muhammad; Zhang, Wuyan; Zhang, Min; Iikuni, Noriko; Alvarez, Daniel F
关节炎
发表日期：2022
文献求助 收藏

Application of the Chelator-Based Clickable Radiotheranostic Platform to Moderate-Molecular-Weight Ligands

基于螯合剂的可点击放射性诊疗平台在中等分子量配体中的应用

期刊:ACS Medicinal Chemistry Letters
影响因子:4
doi:10.1021/acsmedchemlett.2c00320
Nakashima, Kazuma; Iikuni, Shimpei; Watanabe, Hiroyuki; Ono, Masahiro
发表日期：2022
文献求助 收藏

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?

生物类似药之间的转换：其原理和当前经验是什么？

期刊:Drugs
影响因子:14.4
doi:10.1007/s40265-021-01610-1
Mysler, Eduardo; Azevedo, Valderilio Feijó; Danese, Silvio; Alvarez, Daniel; Iikuni, Noriko; Ingram, Beverly; Mueller, Markus; Peyrin-Biroulet, Laurent
发表日期：2021
文献求助 收藏

Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy

接受托法替尼单药治疗、托法替尼联合甲氨蝶呤治疗以及阿达木单抗联合甲氨蝶呤治疗的患者在临床和功能反应方面的异同：一项基于 ORAL Strategy 研究数据的后分析

期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-021-02591-y
Takeuchi, Tsutomu; Fleischmann, Roy; Iikuni, Noriko; Shi, Harry; Soma, Koshika; Paulissen, Jerome; Hirose, Tomohiro; Smolen, Josef S
发表日期：2021
文献求助 收藏

Characterization and Optimization of Benzimidazopyrimidine and Pyridoimidazopyridine Derivatives as Tau-SPECT Probes

苯并咪唑并嘧啶和吡啶并咪唑并吡啶衍生物作为Tau-SPECT探针的表征和优化

期刊:ACS Medicinal Chemistry Letters
影响因子:4
doi:10.1021/acsmedchemlett.1c00071
Watanabe, Hiroyuki; Kishimoto, Takeaki; Kaide, Sho; Tarumizu, Yuta; Tatsumi, Haruka; Iikuni, Shimpei; Ono, Masahiro
发表日期：2021
文献求助 收藏

Structure-Activity and Brain Kinetics Relationships of (18)F-Labeled Benzimidazopyridine Derivatives as Tau PET Tracers

(18)F标记的苯并咪唑并吡啶衍生物作为Tau PET示踪剂的结构-活性和脑动力学关系

期刊:ACS Medicinal Chemistry Letters
影响因子:4
doi:10.1021/acsmedchemlett.0c00641
Watanabe, Hiroyuki; Tarumizu, Yuta; Kaide, Sho; Shimizu, Yoichi; Iikuni, Shimpei; Nakamoto, Yuji; Ono, Masahiro
神经科学
发表日期：2021
文献求助 收藏

Development of a hydroxamamide-based bifunctional chelating agent to prepare technetium-99m-labeled bivalent ligand probes

开发一种基于羟肟酰胺的双功能螯合剂，用于制备锝-99m标记的二价配体探针

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-021-98235-x
Shimizu, Yoichi; Ando, Masato; Iikuni, Shimpei; Watanabe, Hiroyuki; Ono, Masahiro
发表日期：2021
文献求助 收藏

Increased [18F]FMISO accumulation under hypoxia by multidrug-resistant protein 1 inhibitors

耐多药蛋白 1 抑制剂在缺氧条件下增加 [18F]FMISO 的积累

期刊:Ejnmmi Research
影响因子:3.1
doi:10.1186/s13550-021-00752-3
Yoichi Shimizu #, Yukihiro Nakai #, Hiroyuki Watanabe, Shimpei Iikuni, Masahiro Ono, Hideo Saji, Yuji Kuge, Tsuneo Saga, Yuji Nakamoto
表观遗传
发表日期：2021
文献求助 收藏